<DOC>
	<DOCNO>NCT00082472</DOCNO>
	<brief_summary>This study intend show whether inhaled chemotherapy add standard IV chemotherapy regime , investigate additional toxicity show initial evidence efficacy combination .</brief_summary>
	<brief_title>Inhaled Doxorubicin Plus IV Docetaxel Cisplatin Patients With Non-Small-Cell Lung Carcinoma ( NSCLC )</brief_title>
	<detailed_description>Primary Objective Phase I - To determine maximal Phase II dose inhale doxorubicin HCl give combination IV docetaxel cisplatin patient locally advance metastatic unresectable NSCLC previously treat chemotherapy . Primary Objective Phase II - To obtain preliminary evidence therapeutic activity use image study patient measurable evaluable lung lesion serial measurement disease-related pulmonary symptom pulmonary function . Secondary Objective - To define nature toxic effect inhale doxorubicin give combination IV docetaxel cisplatin .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologic cytologic proof locally advance metastatic unresectable NSCLC , Patients pneumonic form BAC , cavitary lesion &gt; 3.5 cm cavitary lesion size air/fluid level eligible . No prior chemotherapy biologic therapy lung cancer Measurable evaluable pulmonary disease require Age &gt; 18 year ECOG performance status 01 Adequate bone marrow , hepatic , renal function Total bilirubin &lt; ULN SGOT and/or SGPT may 2.5 x ULN alkaline phosphatase ≤ ULN , alkaline phosphatase may 4 x ULN SGOT SGPT ≤ ULN Creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 60 mL/min/1.7 m2 BSA Patients must follow pulmonary function test value : DLCO &gt; 50 % predict . ( DLCO must adjust patient ’ hemoglobin ) FVC &gt; 50 % predict FEV1 &gt; 50 % predict Resting oxygen saturation &gt; 90 % Exercise oxygen saturation &gt; 85 % Prior surgery permit provide full recovery occur Patients may receive prior radiotherapy lung . Patients chest wall breast irradiation eligible provide radiographic evidence pulmonary damage attribute radiation therapy . Patients undergone Radioactive Iodine ( RAI ) therapy also eligible . Patients must sign informed consent indicate aware investigational nature study . Women must pregnant breastfeeding study . Men woman reproductive potential must use effective contraceptive method study agree use effective method three month complete chemotherapy . Patients large obstructive pulmonary lesion may cause blockage delivery aerosolize drug affect lung , judgment treat physician . A ventilation scan recommend status unclear . Patients active malignancy . Patients history prior malignancy NSCLC must receive chemotherapy within past 5 year may prior therapy mitomycin ( &gt; 25 mg/m2 ) , bleomycin nitrosoureas ( &gt; 200 mg/m2 ) . The patient may indication pulmonary toxicity chemotherapy . Serious active infection control patient continue manifest symptom despite treatment Patients progressive extrapulmonary metastasis unlikely benefit systemic inhaled chemotherapy , e.g. , extensive liver metastasis , untreated brain metastasis treat brain metastasis clinically stable . If patient receive radiation treatment brain metastasis , least 3 week must elapse since last treatment patient must recover toxicity , receive corticosteroid stable neurologic function corticosteroid . Patients know hypersensitivity platinum compound taxanes drug formulate polysorbate 80 asthma uncontrolled diabetes mellitus Patients undergone lung transplantation unstable angina , congestive heart failure , symptomatic arrhythmias serious illness medical condition judgment investigator compromise patient ’ safety clinically significant neuropathy ( ≥ Grade 1 ) history physical examination Patients use investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Unresectable</keyword>
	<keyword>No Prior Chemotherapy</keyword>
</DOC>